Life Sciences International (LSI) recommends Thermo's £236 million bid
This article was originally published in Clinica
Executive Summary
Life Sciences International has recommended that shareholders accept a £236 million bid for the company from Thermo Instrument Systems (US), the world's leading manufacturer of scientific analytical instruments. Thermo's cash offer of 135p for each LSI share represents a 49% premium on the pre-bid share price.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.